Form 4: Cognition Therapeutics Director Peggy Wallace Granted 34,000 Restricted Stock Units

Cognition Therapeutics Inc. Director Peggy Wallace was granted 34,000 restricted stock units, increasing her beneficial ownership to 86,461 shares.

Summary

• Peggy Wallace, a Director of Cognition Therapeutics Inc. (CGTX), acquired 34,000 shares of Common Stock.
• The acquisition occurred on June 18, 2025.
• These shares are represented by Restricted Stock Units (RSUs), granted at a price of $0.00.
• Following this transaction, Ms. Wallace's total beneficial ownership stands at 86,461 shares.
• The RSUs vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, contingent on her continuous service as a director.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a standard compensation practice aimed at aligning management interests with shareholder value. It does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The grant of 34,000 Restricted Stock Units (RSUs) to Director Peggy Wallace aligns her interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The vesting schedule, contingent on continuous service, incentivizes long-term commitment from a key board member.

Risks

• The value of the granted Restricted Stock Units (RSUs) is subject to the future performance of Cognition Therapeutics Inc.'s common stock, meaning the actual realized value could be lower than the current implied value if the stock price declines.
• Vesting of the RSUs is contingent on continuous service as a director, meaning the units could be forfeited if Ms. Wallace ceases to be a director before the vesting date.

Future Outlook

The Restricted Stock Units granted to Director Peggy Wallace are scheduled to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, provided her continuous service as a director.

Industry Context

This Form 4 filing reflects a standard practice of compensating board members with equity, aligning their incentives with long-term shareholder value. Such grants are common across publicly traded companies, particularly in the biotechnology or pharmaceutical sector where long-term development cycles necessitate sustained commitment from leadership.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of director compensation is a common practice across industries, including the biotechnology sector, aligning director interests with shareholder value.
• While specific compensation levels vary by company size, stage, and industry, equity grants are a standard component of non-executive director remuneration packages.

Related Party Transactions

• The grant of 34,000 Restricted Stock Units (RSUs) to Peggy Wallace, a Director of Cognition Therapeutics Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns their interests with long-term shareholder value, as the value of the RSUs is tied to the company's stock performance.

Next Steps

• The granted Restricted Stock Units (RSUs) are scheduled to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

CGTX, Cognition Therapeutics, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Peggy Wallace